Aim: Assuming that genetic variants of the SLC22A2 and SLC31A1 transporter affect patients' susceptibility to cisplatin-induced ototoxicity, we compared the distribution of 11 SLC22A2 variants and the SLC31A1 variant rs10981694 between patients with and without cisplatin-induced ototoxicity.
Patients & Methods: Genotyping was performed in 64 pediatric patients and significant findings were re-evaluated in 66 adults.
Results: The SLC22A2 polymorphism rs316019 (c.808G>T; Ser270Ala) was significantly associated with protection from cisplatin-induced ototoxicity in the pediatric (p = 0.022) and the adult cohort (p = 0.048; both: Fisher's exact test). This result was confirmed by multiple logistic regression analysis accounting for age which was identified as a relevant factor for ototoxicity as well (rs316019: OR [G/T vs G/G] = 0.12, p = 0.009; age: OR [per year]: 0.84, p = 0.02).
Conclusion: These results identified rs316019 as potential pharmacogenomic marker for cisplatin-induced ototoxicity and point to a critical role of SLC22A2 for cisplatin transport in humans and its contribution to the organ specific side effects of this drug. Original submitted 17 September 2014; Revision submitted 19 December 2014.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865798 | PMC |
| http://dx.doi.org/10.2217/pgs.14.182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization and Otoprotective Effects of Polysaccharides from .
Molecules
January 2025
Department of Pharmacy, University of Pisa, Via Bonanno, 6, 56126 Pisa, Italy.
Hearing loss is one of the most common sensory disorders in humans, and a large number of cases are due to ear cell damage caused by ototoxic drugs including anticancer agents, such as cisplatin. The recent literature reported that hearing loss is promoted by an excessive generation of reactive oxygen species (ROS) in cochlea cells, which causes oxidative stress. Recently, polysaccharides from the cyanobacterium showed many biological activities, including antioxidant activity, suggesting their potential use to combat hearing loss.
View Article and Find Full Text PDFBerberrubine protects against cisplatin-induced ototoxicity by promoting folate biosynthesis.
Front Pharmacol
January 2025
Department of Otolaryngology-Head and Neck Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Objective: This research investigated the possible shielding properties of BB (Berberrubine) against the harmful auditory effects of cisplatin, preliminarily delving into the underlying mechanisms responsible for this protection.
Methods: HEI-OC1 cell viability was determined using a Cell Counting Kit-8 (CCK-8). The impact of BB on cochlear hair cells was studied through cochlear explants culture.
Resveratrol Reduces Cisplatin-induced Cochlear Hair Cell Pyroptosis by Inhibiting the mtROS/TXNIP/NLRP3 Pathway.
Comb Chem High Throughput Screen
January 2025
Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Background: Cisplatin is an effective anti-cancer drug with limited clinical applications due to ototoxicity. Resveratrol, known for its antioxidant and anti-inflammatory properties, has been reported to mitigate these adverse effects, although the underlying mechanism remains under-researched.
Objective: This study aimed to investigate the effects and underlying mechanisms of resveratrol on cisplatin-induced ototoxicity.
Polydopamine Nanohydrogel Decorated Adhesive and Responsive Hierarchical Microcarriers for Deafness Protection.
Adv Sci (Weinh)
January 2025
Department of Otolaryngology Head and Neck Surgery, Nanjing Drum Tower Hospital, Jiangsu Provincial Key Medical Discipline, Nanjing University Medical School, Nanjing, 210008, China.
Cisplatin-induced ototoxicity is attributed to the aberrant accumulation of reactive oxygen species (ROS) within the inner ear. Antioxidants represented by α-lipoic acid (ALA) have been demonstrated to scavenge ROS in the cochlea, while effective delivery of these agents in vivo remains a major challenge. Here, a novel polydopamine (PDA) nanogel decorated adhesive and responsive hierarchical microcarriers for controllable is presented ALA delivery and deafness prevention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!